| The essentials: Pomalyst (pomalidomide, Bristol Myers Squibb) is the third and most potent immunomodulatory drug (IMiD) approved for multiple myeloma, indicated specifically for adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also approved for Kaposi sarcoma. Estimated U.S. annual sales: $2.34 to $3.2 billion depending on measurement period. List price at launch: approximately $24,476 for 21 capsules; a 28-day cycle at the 4 mg dose can exceed $30,000. Generic launches: In March 2026, Breckenridge Pharmaceutical (with NATCO Pharma) and Camber Pharmaceuticals each launched generic pomalidomide capsules in all four dose strengths (1 mg, 2 mg, 3 mg, 4 mg). By mid-2026, at least four generic manufacturers had launched, with more expected. Current generic discount: approximately 23% below brand list price. Historical patterns with oral oncology generics project 50 to 70% discounts once five or more manufacturers are in the market. Critical caveat: the PS-Pomalidomide REMS program applies to all pomalidomide regardless of brand or generic status, due to severe teratogenicity as a thalidomide analogue. Patients cannot obtain generic pomalidomide at a standard retail pharmacy. Specialty pharmacy infrastructure remains the dispensing pathway. |
|---|
| 📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 2 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market. Post 1 covered Xolair (omalizumab) and the arrival of its first interchangeable biosimilar. |
|---|
Multiple myeloma was, for most of the twentieth century, a disease with very limited treatment options. Median survival after diagnosis in the 1970s was roughly two to three years. The available chemotherapy regimens, primarily melphalan and prednisone, produced responses in some patients but rarely deep ones, and the disease almost always came back in a more aggressive form. Patients who relapsed after first-line treatment had few realistic options.
Pomalyst (pomalidomide) is the third immunomodulatory agent to receive FDA approval for myeloma: thalidomide was first in 2003, lenalidomide in 2006, and pomalidomide in 2013. Together that class of drugs, called IMiDs (immunomodulatory drugs), became the backbone of a treatment revolution. Multiple myeloma is still not curable for most patients, but median survival has roughly tripled over the past two decades. Pomalidomide’s specific role is in the relapsed and refractory setting: it is the standard option when both lenalidomide and a proteasome inhibitor have already failed.
In March 2026, the first generic versions of Pomalyst entered the U.S. market. This post covers what pomalidomide is, where it fits in the myeloma treatment landscape, how the cereblon mechanism works, what the clinical evidence shows, why the REMS program persists for generics, and what the entrance of competition is likely to mean for a patient population with enormous financial vulnerability and very limited treatment alternatives.
What Multiple Myeloma Is and Why the Treatment Landscape Matters
Multiple myeloma is a cancer of plasma cells, the mature B cells that live in bone marrow and normally produce antibodies. When plasma cells become malignant, they proliferate uncontrollably, crowding out normal blood cell production, secreting abnormal proteins (monoclonal immunoglobulins or M proteins) that damage kidneys and other organs, and eroding bone through activation of osteoclasts. The result is a disease that attacks from multiple angles simultaneously: anemia from marrow crowding, bone pain and fractures from skeletal destruction, kidney failure from M protein accumulation, and immune suppression from the displacement of normal immune cells.
The American Cancer Society estimated 35,730 new cases of multiple myeloma in the U.S. in 2023. It is predominantly a disease of older adults, with a median age at diagnosis of around 70, and is more common in Black Americans than white Americans at roughly double the incidence rate, a disparity attributed to both genetic and structural factors. The International Myeloma Foundation notes this racial disparity as one of the most significant equity gaps in oncology.
The treatment landscape has been reshaped over the past 20 years by three overlapping drug classes: IMiDs (thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, ixazomib), and monoclonal antibodies (daratumumab, elotuzumab, isatuximab). These classes are now routinely used in combination, producing response rates and survival durations that were not achievable when melphalan-prednisone was the standard of care. CAR-T cell therapy and bispecific antibodies are the newest frontier for heavily pretreated patients.
Pomalidomide occupies a specific niche within this landscape. It is not a first-line drug. Its approved indication is for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, patients who are by definition in later lines of treatment. When pomalidomide is prescribed, the patient has already been through multiple other options. The clinical bar in this population is real, and the drug meets it.
The Science: How Pomalidomide Works
Pomalidomide belongs to the thalidomide analogue family, but understanding it requires moving past the historical context of thalidomide and into the modern molecular biology of what these drugs actually do.
The mechanism centers on a protein called cereblon (CRBN), a substrate receptor of the CRL4-CRBN ubiquitin ligase complex. Every cell manages its protein inventory through the ubiquitin-proteasome pathway: proteins that need to be destroyed are tagged with ubiquitin molecules and delivered to the proteasome for degradation. E3 ubiquitin ligases perform the tagging, guided by substrate adaptor proteins toward specific targets.
When pomalidomide binds to cereblon, it changes which proteins the CRL4-CRBN complex targets for ubiquitination and destruction. Specifically, pomalidomide induces ubiquitination and proteasomal degradation of two key transcription factors: Ikaros (IKZF1) and Aiolos (IKZF3), which regulate immune cell development and homeostasis. The downregulation of Ikaros and Aiolos leads to sequential downregulation of c-Myc followed by IRF4, both transcription factors that myeloma cells depend on for survival. Without them, the malignant plasma cell loses the ability to sustain itself and undergoes apoptosis.
The immune system benefit operates through a parallel pathway. Pomalidomide enhances T cell activation through cereblon-mediated effects on IL-2 and TNF-alpha production, effectively turning up the immune system’s capacity to recognize and attack myeloma cells at the same time it turns off the myeloma cells’ internal survival programs.
Pomalidomide is a third-generation IMiD, more potent than both thalidomide and lenalidomide at inducing cereblon-mediated degradation of Ikaros and Aiolos. Critically, it retains activity in many patients who have become resistant to lenalidomide. While both drugs use the same cereblon mechanism, their binding affinities and degradation kinetics differ enough that lenalidomide resistance does not automatically confer pomalidomide resistance. This is the clinical rationale for its use in the lenalidomide-refractory setting.
Dr. Paul G. Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute, has characterized pomalidomide as filling an unmet need for patients in this setting, a description consistent with the regulatory and clinical data that supported its FDA approval.
| The cereblon mechanism and resistance Patients whose tumors have acquired resistance through cereblon pathway alterations, including low IKZF1 expression, are less likely to respond to pomalidomide and have inferior overall survival. Patients with the lowest quartile of IKZF1 expression show reduced response rates to pomalidomide-dexamethasone and worse survival outcomes. Biomarker-informed prescribing, including cereblon expression assessment, is an active area of research. The next-generation cereblon E3 ligase modulatory drugs (CELMoDs), including iberdomide and mezigdomide, are being studied specifically in patients who have become resistant to pomalidomide through cereblon pathway alterations. |
|---|
What the Clinical Evidence Shows
Pomalidomide is almost always used in combination. The core backbone is pomalidomide plus low-dose dexamethasone (Pd), with additional agents added for more aggressive disease or based on patient characteristics.
The MM-003 trial was the pivotal Phase 3 study supporting Pomalyst’s February 2013 FDA approval. It enrolled 455 patients with relapsed and refractory myeloma who had received at least two prior lines of therapy including lenalidomide and bortezomib, and who had progressed on or within 60 days of their last therapy. Patients were randomized to pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone.
| Regimen | Trial | Key population | ORR | Median PFS |
|---|---|---|---|---|
| Pom + Dex (Pd) | MM-003 | 2 or more prior lines, Len/Bort refractory | approximately 31% vs. 10% control | 15.7 weeks vs. 8 weeks |
| Pom + Bortezomib + Dex (PVd) | OPTIMISMM | 1 to 3 prior lines | 82% | 11.2 months |
| Pom + Daratumumab + Dex (DPd) | APOLLO | 1 or more prior lines, Len-refractory | 69% | 12.4 months |
| Pom + Isatuximab + Dex (IsaPd) | ICARIA-MM | 2 or more prior lines, Len/PI refractory | 60.4% | 11.5 months |
The triplet combinations substantially improved outcomes over doublet therapy, particularly response depth and duration. The CD38 monoclonal antibodies daratumumab and isatuximab have synergized especially well with the pomalidomide backbone, targeting myeloma cells through multiple simultaneous mechanisms.
For MM-003 specifically: the pomalidomide arm achieved an overall response rate of approximately 31% versus 10% for dexamethasone alone, median PFS of 15.7 weeks versus 8 weeks, and median overall survival of 12.7 months versus 8.1 months. In a patient population where both a prior IMiD and proteasome inhibitor had already failed, those are meaningful differences.
The REMS Requirement: What It Is and Why It Applies to Generics Too
This is the most practically important point to understand about pomalidomide’s transition to generic availability: the Risk Evaluation and Mitigation Strategy (REMS) program does not go away when generics launch.
Pomalidomide is only available through the PS-Pomalidomide REMS program because it is a thalidomide analogue. Thalidomide’s teratogenicity is not a historical footnote. In the late 1950s and early 1960s, thalidomide prescribed for morning sickness caused an estimated 10,000 children to be born with severe limb defects worldwide. That history is the reason REMS programs exist as a regulatory category.
Under the REMS requirements:
- Females of reproductive potential must have two negative pregnancy tests before starting pomalidomide treatment: the first within 10 to 14 days prior to initiating therapy, the second within 24 hours prior to prescribing, then weekly during the first month, then monthly thereafter
- Two forms of contraception are required during treatment and for 4 weeks after treatment ends
- Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking pomalidomide and for up to 4 weeks after discontinuing treatment, because pomalidomide is present in semen
- Prescribers must be certified, patients must be enrolled, and pharmacies must verify REMS compliance before dispensing
The generic manufacturers launching pomalidomide in 2026 are required to operate under the same REMS framework. This is not optional and there is no generic shortcut around these requirements. For patients, this means the process of obtaining generic pomalidomide will not feel substantially different from obtaining the brand-name product in terms of safety checkpoints. The paperwork and the monitoring requirements remain identical. The cost is what changes.
The Safety Profile: What Two Decades of IMiD Experience Shows
Pomalidomide’s safety profile is well-characterized from both clinical trials and post-marketing experience with the broader IMiD class.
| Safety item | Details | Clinical guidance |
|---|---|---|
| Embryo-fetal toxicity | Severe: pomalidomide is a known teratogen as a thalidomide analogue. Contraindicated in pregnancy. | REMS enrollment required. Two negative pregnancy tests before initiation. Two contraceptive methods required throughout treatment. |
| Venous and arterial thromboembolism | DVT and PE are common with IMiDs. Risk is elevated with dexamethasone and other combination agents. | Aspirin prophylaxis for low-risk patients; anticoagulation (LMWH or warfarin) for higher-risk patients. Discuss with prescriber before initiating. |
| Neutropenia | Most common grade 3 or 4 hematologic toxicity; occurs in more than 40% of patients in some trials. | Regular CBC monitoring required. Dose adjustments per prescribing information. G-CSF support as clinically indicated. |
| Anemia and thrombocytopenia | Common; reflect both disease burden and treatment effect. | CBC monitoring; transfusion support as needed. |
| Peripheral neuropathy | Less common with pomalidomide than with thalidomide; not a primary concern at typical doses. | Monitoring required; dose modification if neuropathy develops. |
| Infections | Increased risk due to disease-related and treatment-related immune suppression. | PCP prophylaxis and varicella-zoster (shingles) prophylaxis both standard during treatment. |
| Second primary malignancies | Risk observed with IMiD-based regimens; reported in post-marketing data. | Benefit-risk discussion with oncologist; ongoing monitoring. |
The most clinically impactful day-to-day management challenge is thromboembolism risk. IMiDs have a well-established pro-thrombotic effect, and all patients on pomalidomide-containing regimens require some form of anticoagulation or antiplatelet prophylaxis based on their individual risk profile. This must be factored into the treatment plan before the first capsule is dispensed.
The Generic Landscape: Who Has Launched and What Competition Looks Like
The current list price for Pomalyst runs approximately $24,476 for 21 capsules across all dose strengths. At the standard 4 mg dosing, a 28-day cycle can exceed $30,000 before insurance. This is not a drug the uninsured can access without assistance, and even insured patients often face substantial cost-sharing.
The companies that have launched or received FDA approval for generic pomalidomide as of mid-2026:
| Generic manufacturer | Partner | Status |
|---|---|---|
| Breckenridge Pharmaceutical | NATCO Pharma | Launched March 2026; all four dose strengths |
| Camber Pharmaceuticals | — | Launched March 2026; 1 to 4 mg in bottles of 21 |
| Multiple additional manufacturers | Various | FDA-approved; launch timing per settlement agreements |
By mid-2026, approximately six manufacturers had received FDA approval for pomalidomide, with four commercially available. Generic versions are currently priced at approximately $18,900 for 21 capsules, about 23% less than the brand-name price.
That 23% discount is a start, but not the destination. Historical patterns from other oral oncology drugs show that with five or more generic competitors established, discounts in the 50 to 70% range become achievable. Whether that happens within 12 or 36 months depends on how quickly additional manufacturers launch, how aggressively specialty pharmacy benefit managers push conversion, and how Bristol Myers Squibb responds with its own pricing and contracting.
| Why the REMS program changes the generic distribution picture Most generic drugs can be dispensed at any retail pharmacy once approved. Pomalidomide cannot, regardless of brand or generic status. Specialty pharmacies that dispense pomalidomide must be enrolled in the REMS program. This limits distribution to specialty channels and means patients will not be able to fill generic pomalidomide at a standard retail pharmacy. The specialty pharmacy infrastructure remains the dispensing pathway for all versions of the drug. This creates a practical constraint on market dynamics: the competition is among specialty pharmacies enrolled in the REMS program, not the broader retail pharmacy market. For patients, this means the process of switching to a generic requires working within the existing specialty pharmacy network rather than simply requesting a generic substitution at a neighborhood drugstore. |
|---|
What This Means for Patients
Multiple myeloma patients in the relapsed and refractory setting carry high financial toxicity. The term financial toxicity has entered the oncology literature to describe the pattern in which cancer treatment costs create their own form of harm: patients rationing medication, skipping cycles, or declining treatment because of inability to pay. In a disease where treatment continuity directly affects outcomes, financial barriers to access are not just an economic problem. They are a clinical one.
Generic pomalidomide does not immediately solve this. A 23% discount on a $24,000-per-month drug is meaningful in absolute terms but leaves the drug well out of reach for uninsured patients without assistance programs. The insurance infrastructure, prior authorizations, specialty tier cost-sharing, and step therapy requirements, does not simply vanish when a generic enters the market.
What the generic landscape does create is pressure on the entire pricing structure. When specialty pharmacy benefit managers can route patients to lower-cost generic equivalents, net prices for the brand fall through rebate renegotiation. Insurers and PBMs who have been paying full WAC for Pomalyst now have leverage they did not have before. Formulary preferences will shift. Over 24 to 36 months, the realistic net cost of pomalidomide therapy across all payers should be materially lower than it was when the brand held exclusive market position.
For patients currently on Pomalyst: if your insurer notifies you of a formulary switch to generic pomalidomide, the clinical content of your treatment is not changing. The active ingredient, the dosing, the REMS requirements, and the safety monitoring are identical. A brief conversation with your oncologist to confirm the transition is prudent, not because the generic is inferior, but because any change in an active treatment regimen is worth documenting.
For patients who have been told pomalidomide could be part of their treatment plan but have faced access barriers: the middle of 2026 and into 2027 is the period to revisit. Ask your oncologist and your specialty pharmacy specifically about generic pomalidomide availability and current pricing. The BMS patient assistance program for Pomalyst may also have adjusted its thresholds as generic competition has entered. Eligible commercially insured patients may pay as little as $0 per one-month supply through the BMS copay assistance program, up to a maximum benefit of $15,000 per calendar year.
Where Pomalidomide Fits in the Evolving Myeloma Landscape
A caveat worth stating explicitly: generic pomalidomide becoming more affordable does not mean pomalidomide is the right treatment for every relapsed and refractory myeloma patient in 2026. The treatment landscape continues to evolve rapidly.
CAR-T cell therapies targeting BCMA, including ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma), have produced deep and durable responses in heavily pretreated patients and are moving earlier in the treatment sequence. Bispecific antibodies targeting BCMA or GPRC5D, including teclistamab, elranatamab, and talquetamab, are showing impressive response rates as outpatient therapies without the manufacturing lead time of CAR-T. The IMiD class is not being replaced; it is increasingly being used in conjunction with these newer modalities.
CELMoDs, the next-generation cereblon E3 ligase modulatory drugs developed to overcome IMiD resistance, represent the class’s own frontier. Drugs like iberdomide and mezigdomide are being studied in patients who have become resistant to pomalidomide through cereblon pathway alterations, taking the same fundamental biology and engineering around the resistance mechanisms that limit pomalidomide’s long-term utility.
The value of generic pomalidomide is not only that it makes an existing drug cheaper. It makes a drug with meaningful clinical activity in a population of patients who have run through other options available to more of the patients who need it, at a moment when it may be combined with newer agents in ways that were not available when Pomalyst first launched in 2013.
For related HED coverage on the biosimilar and generic drug access landscape in 2026, see our post on the first generic venetoclax approval and what it means for CLL and AML patients and Post 1 of this series covering Xolair (omalizumab) and its first interchangeable biosimilar.
Sources
Breckenridge/NATCO launch announcement: Breckenridge Pharmaceutical Launches Pomalidomide Capsules in the United States. BioSpace. March 2, 2026.
Camber launch: Camber launches generic Pomalyst. Drug Store News. March 2026.
NATCO Pharma sales data: Natco Pharma launches generic blood cancer treatment in US. Business Standard. March 3, 2026.
Generic availability (Drugs.com): Generic Pomalyst Availability. drugs.com.
Pricing data: Pomalyst Prices, Coupons, Copay Cards and Patient Assistance. drugs.com.
LOE market context (Optum Rx): Blockbuster drug patent expirations in 2026 and what they mean. business.optum.com. April 2026.
Pomalidomide mechanism (IKZF1/IKZF3/cereblon): Kronke J et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305. doi:10.1126/science.1244851.
IMiD mechanisms review: Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs. 2017. PMID 28205024.
Cereblon/Ikaros/Aiolos degradation kinetics: Zhu YX et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide. Blood Cancer Journal. 2015.
Pomalyst prescribing information and REMS: POMALYST (pomalidomide) capsules Prescribing Information. Bristol Myers Squibb.
PS-Pomalidomide REMS program: POMALYST REMS. pomalyst-rems.com.
FDA REMS resources: REMS Program Resources. FDA.gov.
Thalidomide teratogenicity: Thalidomide. StatPearls. NCBI.
Cereblon mechanism review: Cereblon and IMiD pharmacology. PMC4565721.
Ubiquitin-proteasome pathway: Ubiquitin-Proteasome Pathway. StatPearls. NCBI.
Proteasome inhibitors in myeloma: Proteasome Inhibitors in Multiple Myeloma. PMC6360300.
CD38 monoclonal antibodies: Anti-CD38 Therapies in Multiple Myeloma. PMC7248059.
Financial toxicity in oncology: Financial Toxicity in Cancer Care. PMC6354973.
DVT/PE risk with IMiDs: Thromboembolism. StatPearls. NCBI.
Neutropenia: Neutropenia. StatPearls. NCBI.
Multiple myeloma overview: Multiple Myeloma. American Cancer Society.
Carvykti FDA approval: FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. FDA.gov.
BMS patient assistance: BMS Access Support. bmsaccesssupport.bmscustomerconnect.com.
Patient resources: International Myeloma Foundation | Multiple Myeloma Research Foundation | HealthWell Foundation
| Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Multiple myeloma treatment decisions are complex and highly individualized. Patients should consult their hematologist-oncologist before making any changes to their treatment regimen. Drug pricing information reflects figures at time of publication and is subject to change. |
|---|
